Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients

NCT04432688 is registered in ClinicalTrials.gov with Marubeni Pharmaceuticals (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT04432688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04432688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients
Lead sponsor
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Phase
Observational
Overall status
Completed
Start date
December 1, 2020
Completion date
June 18, 2023
Enrollment
3,192 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia